The mission of the group is to identify early-stage companies with disruptive technologies that solve unmet needs in biologic drug R&D and production, as well as challenges in the diagnostics market. Investment selection is completed thorough a rigorous review process, which starts with in-depth market work, followed by due diligence according to Danaher’s best-in-class standard work.
